CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its unaudited financial results for the quarter ended June 30, 2017 on Monday, August 14, 2017, after the US markets close.
The Company will host a conference call on Monday, August 14, 2017 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph Goldwasser, Chief Financial Officer. The conference call will be available via webcast and can be accessed through Myomo’s Investor Relations page. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
To dial into the conference call, please dial 1-866-807-9684 from the U.S. or 1-412-317-5415 internationally. Please instruct to be joined into Myomo’s earnings conference call. A replay of the conference call will be available approximately one hour after completion of the live conference call at the Investor Relations page. A dial-in replay of the call will be available until August 28, 2017; please dial 1-877-344-7529 from the U.S. or 1-412-317-0088 internationally and provide the passcode of 10111308.
About Myomo
Myomo, Inc. is a commercial stage medical
robotics Company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Based on patented
technology developed at MIT and the Company, Myomo develops and markets
the MyoPro® product line of lightweight, non-invasive, powered arm
braces to restore function in the paralyzed or weakened arms and hands
of individuals that have suffered a stroke, spinal cord or nerve injury
such as brachial plexus injury, or other neuromuscular disability such
as amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). It is
provided through clinical relationships with VA medical centers, leading
rehabilitation hospitals, and Orthotics and Prosthetics (“O&P”)
practices. Several hundred have been successfully used by patients. It
is the only device that, sensing a patient’s own neurological signals
through non-invasive sensors on the arm, can restore their ability to
use their arms and hands so that they can return to work, live
independently and reduce their cost of care. Myomo is headquartered in
Cambridge, Massachusetts, with sales and clinical professionals across
the U.S. For more information, please visit www.myomo.com.
Forward Looking Statements
This press release contains
forward-looking statements regarding the Company's future business
expectations, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Other risks and uncertainties
include, among others, risks related to new products, services, and
technologies, government regulation and taxation, and fraud. More
information about factors that potentially could affect Myomo's
financial results is included in Myomo's filings with the Securities and
Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
